The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient?
The standard of care for early-stage lung cancer is surgical resection. Many patients with this diagnosis have comorbidities that preclude oncologic resection. Randomized data show that limited resection is inadequate for local disease control and may negatively impact on survival. Stereotactic body radiotherapy (SBRT) has emerged as a novel radiation modality with significant applications in the inoperable, early-stage lung cancer population. Retrospective and prospective studies published in the past decade have established the feasibility, safety, and efficacy of SBRT in these patients using a variety of dose regimens and technologies. To date, lung SBRT results demonstrate excellent local control with very little acute toxicity, and suggest improved overall survival compared to historical controls of fractionated radiotherapy. Ongoing prospective trials are exploring dose and fractionation schedules in the inoperable population, and are starting to explore the role of SBRT for the operable patient.
Videtic
Gregory M M
GM
Cleveland Clinic Lerner College of Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. videtig@ccf.org
Stephans
Kevin L
KL
D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008168:Lung / Q000473:pathology / Q000528:radiation effects; D008175:Lung Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D016634:Radiosurgery / Q000379:methods*; D016896:Treatment Outcome
Cancer. 1987 Jun 1;59(11):1874-81
3032394
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):789-95
19473777
J Thorac Cardiovasc Surg. 1973 Oct;66(4):563-72
4356889
Ann Thorac Surg. 2008 Feb;85(2):S733-6
18222206
Acta Oncol. 1994;33(6):677-83
7946448
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):47-54
18977095
Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):677-82
19251380
J Thorac Oncol. 2009 Aug;4(8):976-82
19633473
Lung Cancer. 2001 Dec;34 Suppl 3:S39-43
11740992
Cancer. 1998 Feb 1;82(3):433-8
9452258
Radiother Oncol. 2005 Oct;77(1):83-7
16209896
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1427-31
16169670
J Clin Oncol. 2006 Oct 20;24(30):4833-9
17050868
J Thorac Cardiovasc Surg. 2005 Apr;129(4):813-8
15821648
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1241-56
15519797
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1057-65
17905527
Radiother Oncol. 2009 Dec;93(3):408-13
19454366
Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1283-6
19028267
Cancer. 2010 Jan 15;116(2):406-14
19950125
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):404-9
18394819
Oncology (Williston Park). 2004 Oct;18(11):1419-30; discussion 1430, 1432, 1435-6
15609470
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):349-54
19427551
Cancer. 2009 Feb 1;115(3):587-94
19130457
Lancet. 1997 Jul 19;350(9072):161-5
9250182
Chest. 2003 Nov;124(5):1946-55
14605072
Ann Thorac Surg. 2005 Dec;80(6):2051-6; discussion 2056
16305843
Lung Cancer. 1999 Apr;24(1):31-7
10403692
Thorac Surg Clin. 2007 May;17(2):251-9
17626403
Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):666-70
11597807
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):796-801
19427740
JAMA. 2010 Mar 17;303(11):1070-6
20233825
Ann Thorac Surg. 1987 Oct;44(4):340-3
2821937
Lung Cancer. 2003 Jul;41(1):1-11
12826306
Ann Thorac Surg. 2006 Mar;81(3):1013-9; discussion 1019-20
16488712
Surgery. 2003 Oct;134(4):691-7; discussion 697
14605631
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):685-92
18164849
Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3
7677489
J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S118-24
17603307
J Thorac Oncol. 2009 Jul;4(7):838-44
19487961
Chest. 2002 Apr;121(4):1155-8
11948046
Acta Oncol. 2006;45(7):787-95
16982541
Radiother Oncol. 2009 Jun;91(3):360-8
19410314
J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S94-100
17603311